Potassium competitive acid blockers in Barrett's esophagus: lessons from gastro-esophageal reflux disease and future directions
{{output}}
Barrett's esophagus (BE) is a metaplastic condition predisposing to esophageal adenocarcinoma. Currently, proton pump inhibitors are a mainstay of therapy for gastro-esophageal reflux disease (GERD), a known risk factor for BE, and as a chemopreventive agent ... ...
